Patient Guide: A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)

Why Use Quri.ai for This Trial?

  • ✓ Simplified eligibility checker - know if you qualify in minutes
  • ✓ Direct contact with study coordinators at 18 locations
  • ✓ Plain language explanations of medical terms and procedures
  • ✓ Personalized enrollment support throughout your journey
  • ✓ Free service - no hidden fees or obligations
Trial ID: NCTNCT06041802
Status: 🟢 Enrolling Now
Condition: Carcinoma, Carcinoma, Squamous Cell
Phase: PHASE2

Where You Can Participate

This study is available at 18 locations across the country.

Top locations include:
  • • Nagoya, Aichi
  • • Sapporo, Hokkaido
  • • Yokohama, Kanagawa
  • • And 15 more locations

Loading interactive enrollment tools...

The full interactive experience will load momentarily

A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39) - Join Clinical Trial NCTNCT06041802

How to Join This Clinical Trial - NCTNCT06041802

Learn how to participate in this PHASE2 trial studying an investigational therapy for Carcinoma, Carcinoma, Squamous Cell. This study is currently enrolling participants.

Am I Eligible for This Clinical Trial?

This clinical research study is looking for participants with Carcinoma, Carcinoma, Squamous Cell. Eligibility requirements include specific age ranges, health status, and medical history. Contact the study team to learn if you qualify.

Condition Being Studied
Carcinoma, Carcinoma, Squamous Cell
Treatment Being Tested
Investigational treatment
Study Phase
PHASE2 - Safety and effectiveness study
Enrollment Status
Currently enrolling participants
Study Identifier
NCTNCT06041802 - ClinicalTrials.gov Identifier
Sponsored By
Study sponsor

What to Expect as a Participant

Participating in this clinical trial involves:

  • Initial screening to determine eligibility
  • Regular study visits and health assessments
  • Receiving the study treatment or placebo
  • Medical monitoring and follow-up care
  • Contributing to medical research that may help others
  • Potential access to new treatments before they're widely available

Clinical Trial Benefits and Compensation

Participants in this clinical research study may receive:

  • Close medical monitoring by healthcare professionals
  • Access to potential new treatments
  • Compensation for time and travel (varies by study)
  • No-cost study-related medical care
  • The opportunity to help advance medical knowledge

Where Is This Clinical Trial Located?

This study is enrolling participants at 18 locations. Find a study site near you:

Clinical Research Site

Nagoya, Aichi 466-8560 - Japan

Status: RECRUITING

Clinical Research Site

Sapporo, Hokkaido 060-8543 - Japan

Status: RECRUITING

Clinical Research Site

Yokohama, Kanagawa 236-0004 - Japan

Status: RECRUITING

Clinical Research Site

Sendai, Miyagi 980-8574 - Japan

Status: RECRUITING

Clinical Research Site

Matsumoto, Nagano 390-8621 - Japan

Status: RECRUITING

Clinical Research Site

Niigata-shi, Niigata 951-8566 - Japan

Status: RECRUITING

Clinical Research Site

Hidaka, Saitama 350-1298 - Japan

Status: RECRUITING

Clinical Research Site

Izumo, Shimane 693-8501 - Japan

Status: RECRUITING

Clinical Research Site

Nagaizumi-cho,Sunto-gun, Shizuoka 411-8777 - Japan

Status: RECRUITING

Clinical Research Site

Chuo-ku, Tokyo 104-0045 - Japan

Status: RECRUITING

And 8 more locations available. Contact us to find the nearest participating site.

How to Enroll in This Study

To learn more about participating in this PHASE2 clinical trial for Carcinoma, Carcinoma, Squamous Cell:

  1. Review the eligibility criteria with your healthcare provider
  2. Contact the study team for a pre-screening interview
  3. Schedule an in-person screening visit if eligible
  4. Review and sign the informed consent form
  5. Begin participation in the clinical trial

Why Choose Quri.ai Study Finder

Quri.ai's Study Finder is the leading clinical trial business intelligence platform, helping BD professionals:

  • Discover clinical trials before competitors
  • Access exclusive contact information
  • Track sponsor pipelines and opportunities
  • Connect with decision makers directly
  • Win more business partnerships